



(11) **EP 2 314 625 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

(15) Correction information:
Corrected version no 1 (W1 A2)
Corrections, see
Bibliography
Corrected Kind of Document code A2
Previously published as A1

(51) Int Cl.:
C07K 16/24 ^(2006.01) **C07K 16/00** ^(2006.01)
C07K 16/28 ^(2006.01) **A01K 67/027** ^(2006.01)

(48) Corrigendum issued on:
22.06.2011 Bulletin 2011/25

(43) Date of publication:
27.04.2011 Bulletin 2011/17

(21) Application number: **10182935.6**

(22) Date of filing: **03.12.1997**

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE

(30) Priority: **03.12.1996 US 759620**

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
04013481.9 / 1 500 329
97953227.2 / 0 942 968

(71) Applicant: **Amgen Fremont Inc.**
Fremont, CA 94555 (US)

(72) Inventors:
• **Green, Larry**
San Francisco, CA 94114 (US)

- **Jakobovits, Aya**
Menlo Park, CA 94025 (US)
- **Kucherlapati, Raju**
Weston, MA 02493 (US)
- **Klapholz, Sue**
Stanford, CA 94305 (US)
- **Mendez, Michael**
El Granada, CA 94018 (US)

(74) Representative: **Vossius & Partner**
Siebertstrasse 4
81675 München (DE)

Remarks:

This application was filed on 30-09-2010 as a
divisional application to the application mentioned
under INID code 62.

(54) **Transgenic mammals having human Ig loci including plural VH and V kappa regions and antibodies produced therefrom**

(57) The present invention relates to transgenic non-human animals that are engineered to contain human immunoglobulin gene loci. In particular, animals in accordance with the invention possess human Ig loci that includes plural variable (VH and V kappa) gene regions. Advantageously, the inclusion of plural variable region genes enhances the specificity and diversity of human

antibodies produced by the animal. Further, the inclusion of such regions enhances and reconstitutes B-cell development to the animals, such that the animals possess abundant mature B-cells secreting extremely high affinity antibodies.

EP 2 314 625 A8